CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a rare disease therapeutics company ("Zevra"), today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of $6.50 per share, for total gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions. Cantor and William Blair are acting as joint book-running managers for the offering. Citizens JMP and H.C. Wainwright & Co. are acting as co-managers. The securities described above are being offered by Zevra pursuant to a registration statement on Form S-3 (Registration No. 333- 279941), which was filed with the Securities and Exchange Commission (the "SEC") on June 4, 2024, and became effective on June 13, 2024. This offering is being made only by means of a prospectus supplement and accompanying prospectus which forms a party of the registration statement. A final prospectus supplement related to the offering will be filed with the SEC and may be obtained, when available, by visiting the SEC's website at http://www.sec.gov